<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104323">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02061761</url>
  </required_header>
  <id_info>
    <org_study_id>CA224-022</org_study_id>
    <nct_id>NCT02061761</nct_id>
  </id_info>
  <brief_title>Safety Study of Anti-LAG-3 in CLL, HL and NHL</brief_title>
  <official_title>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, dose limiting
      toxicities and maximum tolerated dose of BMS-986016 administered to subjects with relapsed
      or refractory chronic lymphocytic leukemia and lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Lymphocytic Leukemia (CLL)

      Hodgkin Lymphoma (HL)

      Non-Hodgkin Lymphoma (NHL)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety measured by the rate of Adverse events (AEs), Serious Adverse events (SAEs), death and laboratory abnormalities</measure>
    <time_frame>Up to approximately 2.3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration observed at the end of infusion (Ceoinf) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of a dosing interval (Ctau) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of followup (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff AUC) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of Cmax accumulation observed (T-HALFeff Cmax) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index; ration of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ceoinf accumulation index; ratio of Ceoinf at steady state to Ceoinf after the first dose (AI_Ceoinf) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016</measure>
    <time_frame>24 timepoints up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of BMS-986016</measure>
    <time_frame>Up to 135 day of follow-up (approximately 2.3 years)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity (ADA): The proportion of subjects who are anti-drug antibody (ADA)-positive at baseline, the proportion of subjects who become ADA-positive on study, and the proportion of subjects who remain ADA-negative to BMS-986016</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 1.9 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR is the proportion of subjects with a best overall response of Complete Response (CR) or Partial Response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 1.9 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>DOR based on current criteria relevant to each disease type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark progression-free survival rate (PFSR)</measure>
    <time_frame>Approximately 1.9 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>BMS-986016</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Dose Escalation: BMS-986016 20,80,240, 800 mg solution intravenously every 2 weeks during each 8 week cycle, up to 12 cycles
Part B: Dose Expansion: BMS-986016 dose selected from Part A solution intravenously every 2 weeks during each 8 week cycle, up to 12 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986016</intervention_name>
    <arm_group_label>BMS-986016</arm_group_label>
    <other_name>Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Part A:

               -  Chronic Lymphocytic Leukemia

               -  Hodgkin Lymphoma

               -  Non Hodgkin Lymphoma

          -  Part B:

               -  Chronic Lymphocytic Leukemia

               -  Hodgkin Lymphoma

               -  Diffuse Large B-cell Lymphoma

               -  Mantle Cell Lymphoma

          -  Progressed, or been refractory to at least one prior standard therapy, including
             radiation, immunotherapy, cytotoxic chemotherapy, and select antibody (anti-CD20,
             Alemtuzumab, or Brentuximab) therapy

          -  Not eligible for or declined transplantation or any standard therapy known to be life
             prolonging or life saving

          -  Subjects without prior exposure to immune cell modulating antibody regimens such as
             anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death
             protein 1 (PD-1), anti-programmed cell death protein ligand 1 (PD-L1), anti-PD-L2,
             anti-KIR, anti-CD137, or anti-OX40 antibodies.  Prior anti-CD20, Alemtuzumab or
             Brentuximab antibody therapy is allowed

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  At least 1 lesion with measurable disease

          -  Willing to consent to allow a pre-treatment bone marrow biopsy

          -  Willing to consent to a pre-treatment tumor biopsy or allow the acquisition of an
             existing tumor sample

        Exclusion Criteria:

          -  Primary cutaneous lymphoma, lymphoproliferative diseases associated with primary
             immune deficiencies, and lymphomas associated with human immunodeficiency virus (HIV)
             infection

          -  Known or suspected central nervous system (CNS) metastases or with the CNS as the
             only site of active disease (controlled CNS metastases are allowed)

          -  Autoimmune disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Armand, Site 0004</last_name>
      <phone>617-632-2368</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay Gopal, Site 0001</last_name>
      <phone>206-288-2037</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
